ATE403006T1 - Verwendung eines adenovirusvektors zur transduktion von synovialen zellen - Google Patents

Verwendung eines adenovirusvektors zur transduktion von synovialen zellen

Info

Publication number
ATE403006T1
ATE403006T1 AT00908116T AT00908116T ATE403006T1 AT E403006 T1 ATE403006 T1 AT E403006T1 AT 00908116 T AT00908116 T AT 00908116T AT 00908116 T AT00908116 T AT 00908116T AT E403006 T1 ATE403006 T1 AT E403006T1
Authority
AT
Austria
Prior art keywords
adenovirus
transducing
adenovirus vector
tissue tropism
synovial cells
Prior art date
Application number
AT00908116T
Other languages
English (en)
Inventor
Ronald Vogels
Govert Schouten
Abraham Bout
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE403006T1 publication Critical patent/ATE403006T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211Thymidine kinase (2.7.1.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT00908116T 1999-03-04 2000-03-03 Verwendung eines adenovirusvektors zur transduktion von synovialen zellen ATE403006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200624 1999-03-04

Publications (1)

Publication Number Publication Date
ATE403006T1 true ATE403006T1 (de) 2008-08-15

Family

ID=8239945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00908116T ATE403006T1 (de) 1999-03-04 2000-03-03 Verwendung eines adenovirusvektors zur transduktion von synovialen zellen

Country Status (7)

Country Link
EP (1) EP1159438B1 (de)
JP (1) JP4683727B2 (de)
AT (1) ATE403006T1 (de)
AU (1) AU776067B2 (de)
CA (1) CA2364499C (de)
DE (1) DE60039683D1 (de)
WO (1) WO2000052186A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
DE60043126D1 (de) * 1999-05-17 2009-11-19 Crucell Holland Bv Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1067188A1 (de) * 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
ATE315095T1 (de) * 2000-08-10 2006-02-15 Crucell Holland Bv Adenovirenvektoren zur transduktion der chondrozyten
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (de) * 2000-10-06 2002-04-10 Introgene B.V. Genverabreichung-Vektoren für Stammzellen
EP1279738A1 (de) * 2001-07-06 2003-01-29 Crucell Holland B.V. Für mesenchymale Stammzellen spezifische Gen-Transfer-Vektoren
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (de) 2002-10-23 2005-07-20 Crucell Holland B.V. Einstellung für rekombinante adenovirus-basierte impfstoffe
AU2003298361B2 (en) 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
EP2971008B1 (de) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen
CA3000462C (en) 2015-10-05 2024-04-02 Salk Institute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
NZ759833A (en) 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
IL124654A0 (en) * 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (de) * 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen

Also Published As

Publication number Publication date
EP1159438B1 (de) 2008-07-30
WO2000052186A1 (en) 2000-09-08
JP2002537816A (ja) 2002-11-12
AU2948800A (en) 2000-09-21
JP4683727B2 (ja) 2011-05-18
CA2364499A1 (en) 2000-09-08
AU776067B2 (en) 2004-08-26
EP1159438A1 (de) 2001-12-05
DE60039683D1 (de) 2008-09-11
CA2364499C (en) 2008-12-23

Similar Documents

Publication Publication Date Title
ATE403006T1 (de) Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
Nakamura et al. Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
US9023617B2 (en) Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
WO2001005434A3 (en) Hyaluronic acid-protein conjugates
HUP0204544A2 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2292771A3 (de) Sense mRNA Therapie
DK1345959T3 (da) Membranscaffoldproteiner
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
DE69520448D1 (de) Adenovirus-aav zwittervirus sowieverfahrungen zur verwendung davon
DE59913833D1 (de) Strukturprotein von aav, seine herstellung und verwendung
JP2002537816A5 (de)
US20220249346A1 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
WO2000061736A3 (en) Recombinant and mutant marek's disease virus
DE69516416T2 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
NO995697D0 (no) Gen-vektorer
Moschcovich et al. Folding and activity of recombinant human procollagen C‐proteinase enhancer
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
PT1294874E (pt) Variantes de cd154 e as suas utilizacoes
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE331794T1 (de) Humane prostacyclinsynthase
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1999009177A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
FR2756491B1 (fr) Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties